Precede Biosciences

Precede Biosciences is a US-based startup that has been making strides in the field of precision medicine with its innovative liquid biopsy platform. The company, founded in 2005, aims to address the significant gaps in accessing and understanding disease-defining biology at crucial times. Their breakthrough comes in the form of a revolutionary blood test that uncovers actionable disease-defining transcriptional biology. The startup's unique genome-wide platform profiles circulating chromatin and the DNA methylome, providing insights into the dynamic activity of individual genes and pathways in diseased tissues using just 1mL of plasma. By collaborating with developers of new medicines and advancing their own diagnostic tests, Precede Biosciences envisions a future where healthcare advancements are more successful, and where individuals can receive precise, minimally invasive diagnosis and treatment tailored to the biology of their disease. The company recently secured a significant $57.00M Series A investment on 05 October 2023, demonstrating strong investor support. Notable investors in this round include Lilly Asia Ventures, 5AM Ventures, Illumina Ventures, Osage University Partners, Qatar Investment Authority, Binney Street Capital, and Bristol-Myers Squibb. With its focus on biopharma, biotechnology, and healthcare, Precede Biosciences is poised for further growth and impact in the realm of precision medicine.